Top entities: Rhythm Pharmaceuticals, Handa Oncology, United States — Food and Drug Administration, Exelixis, Bill Liu.

What category does this event fall under?

Regulatory — classified as regulatory approval.

What is the sentiment of coverage?

Aggregate sentiment score: 40 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Jul 31, 2026. Coverage continues to evolve.

Regulatory regulatory approval

FDA tentative approval for OMCAZIO capsules

Q: When did this event occur?

First reported Jul 31, 2026; last updated Jul 31, 2026.

Q: What is the market impact?

General. The tentative approval of OMCAZIO positions Rhythm Pharmaceuticals to enter the competitive oncology market with a differentiated formulation of cabozantinib, potentially capturing market share from Exelixis' CABOMETYX.

Analysis based on 6 articles · First reported Jul 31, 2026 · Last updated Jul 31, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The tentative approval of OMCAZIO positions Rhythm Pharmaceuticals to enter the competitive oncology market with a differentiated formulation of cabozantinib, potentially capturing market share from Exelixis' CABOMETYX. This regulatory progress is likely to positively impact Handa's stock and commercial prospects, while posing a competitive threat to Exelixis.

Pharmaceuticals Biotechnology Healthcare

Event Summary

On July 31, 2026, Rhythm Pharmaceuticals, Inc. announced that the United States — Food and Drug Administration (FDA) granted tentative approval to OMCAZIO (cabozantinib) capsules, a novel alternate-salt formulation of cabozantinib developed by Handa's U.S. subsidiary, Handa Oncology, LLC. OMCAZIO is indicated for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and certain neuroendocrine tumors. The drug was developed under Section 505(b)(2) and is bioequivalent to Exelixis' CABOMETYX at a lower dose, with no clinically significant food effect and improved absorption. Tentative approval indicates the FDA has determined the application meets standards for safety, effectiveness, and manufacturing quality, but final approval is still required before commercial distribution. Handa's Chairman and CEO, Bill Liu, stated the company is continuing commercial readiness activities and looks forward to making OMCAZIO available following final approval. The approval is a significant regulatory milestone for Handa, potentially offering an alternative to the established CABOMETYX product.

Key Actions

100 United States — Food and Drug Administration granted tentative approval Handa Oncology

Entities Involved

stock

Rhythm Pharmaceuticals

Rhythm Pharmaceuticals is the developer and sponsor of OMCAZIO. The tentative approval is a major regulatory milestone that advances its oncology pipeline and commercial prospects.

Importance 100.0 Sentiment 70.0

priv

Handa Oncology

Handa Oncology, the U.S. subsidiary, is the recipient of the tentative approval and will be responsible for commercializing OMCAZIO in the United States.

Importance 90.0 Sentiment 70.0

govactor

United States — Food and Drug Administration

The FDA granted tentative approval, validating the safety, effectiveness, and manufacturing quality of OMCAZIO. This action is part of its regulatory oversight role.

Importance 80.0 Sentiment 0.0

stock

Exelixis

Exelixis markets CABOMETYX, the reference product to which OMCAZIO is bioequivalent. The approval of a lower-dose alternative could increase competition and pressure its market share.

Importance 60.0 Sentiment -20.0

per

Bill Liu

Bill Liu, Chairman and CEO of Handa, is the public spokesperson for the company. His leadership is central to the company's strategic direction and commercial readiness.

Importance 40.0 Sentiment 50.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard